Analysts Viewpoint Investing in Compass Therapeutics Inc (CMPX) Is Getting More Attractive Compass Therapeutics Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on
Analysts Viewpoint CMPX stock price expected to increase by 6 in 12 months Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Insiders Updates Leerink Partners upgrades Compass Therapeutics Inc (CMPX) rating to an Outperform Compass Therapeutics Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on